Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma has demonstrated a strong financial position, ending the quarter with cash, cash equivalents, and marketable securities totaling $320 million, reflecting a $23 million increase quarter-over-quarter attributed to a private placement. The company has solidified the profile of its key product candidate, rondecabtagene autoleucel (ronde-cel), as a leader in durability for CD19/CD20 CAR T-cell therapies, which positions it favorably against competitors. Additionally, expert feedback on Lyell’s existing LYL273 dataset suggests that the company's product candidates are achieving clinical success in challenging markets, validating its potential for growth and enhancing the overall outlook for the stock.

Bears say

Lyell Immunopharma has reported a decrease in research and development expenses, which fell to $28.2 million in the third quarter of 2025 from $34.9 million in the second quarter, suggesting potential budget constraints. There are several significant risks associated with the company's pipeline, including challenges in capturing market share in the CAR-T market, potential efficacy deterioration, unforeseen safety events, and long-term dilution risks that could impact investor confidence. Furthermore, the lack of definitive evidence regarding the durability of the treatment outcomes and the management of associated toxicities raises concerns about the company's ability to establish its therapies as standard-of-care options in a competitive and lucrative market.

Lyell Immunopharma (LYEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.